High Quality Solithromycin CAS NO (760981-83-7) Available For Sale

Solithromycin, with the Chemical Abstracts Service (CAS) number 760981-83-7, is a novel macrolide antibiotic that exhibits broad-spectrum activity against a variety of Gram-positive, Gram-negative, atypical, and intracellular bacteria. It belongs to the ketolide class of antibiotics and is derived from the macrolide antibiotic erythromycin. Solithromycin has garnered attention for its potent antibacterial activity and favorable pharmacokinetic profile, making it a promising candidate for the treatment of respiratory tract infections and other bacterial diseases.

1. Chemical Structure Solithromycin is a semi-synthetic derivative of erythromycin and features a modified 3-keto group and an alkyl-aryl side chain substitution. This structural modification enhances its binding affinity to the bacterial ribosome and confers improved stability and potency compared to traditional macrolide antibiotics.

2. Mechanism of Action Similar to other macrolide antibiotics, solithromycin acts by binding to the bacterial 50S ribosomal subunit, thereby inhibiting protein synthesis and impeding bacterial growth and replication. Its unique chemical structure allows for effective penetration into bacterial cells and offers activity against macrolide-resistant strains.

3. Broad Spectrum of Activity Solithromycin exhibits potent activity against various bacterial pathogens, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Legionella pneumophila, Mycoplasma pneumoniae, Chlamydia pneumoniae, and atypical pathogens such as Mycobacterium avium complex (MAC). This broad spectrum of activity makes it suitable for the treatment of respiratory tract infections, community-acquired pneumonia, and sexually transmitted infections.

4. Pharmacokinetics Solithromycin is characterized by favorable pharmacokinetic properties, including high oral bioavailability, extensive tissue penetration, and a prolonged half-life, allowing for convenient once-daily dosing. It is metabolized primarily by hepatic enzymes and excreted via both renal and biliary routes.

5. Clinical Efficacy Clinical trials have demonstrated the efficacy and safety of solithromycin in the treatment of various bacterial infections, including community-acquired pneumonia, acute bacterial sinusitis, and uncomplicated gonorrhea. Its potent antibacterial activity and favorable tolerability profile make it a valuable addition to the armamentarium of antibiotics.

6. Resistance Profile While solithromycin has shown activity against macrolide-resistant strains of bacteria, including those harboring the erm and mef genes, the emergence of resistance remains a concern. Continued surveillance and judicious use of solithromycin are essential to mitigate the development and spread of resistance.

7. Safety and Tolerability Overall, solithromycin is well tolerated, with adverse effects typically being mild to moderate in severity. Common side effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea, as well as transient elevations in liver enzymes. Serious adverse events are rare but may include hepatotoxicity and QT interval prolongation.

8. Regulatory Approval Solithromycin has received regulatory approval in some countries for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. However, regulatory agencies have raised concerns regarding potential hepatotoxicity and have recommended further evaluation of its safety profile.

9. Future Directions Research into solithromycin continues to explore its clinical utility and potential applications in the treatment of bacterial infections. Future studies may focus on optimizing dosing regimens, evaluating its efficacy in special patient populations, and investigating its role in combination therapy for multidrug-resistant infections.

10. Conclusion Solithromycin represents a promising new addition to the arsenal of antibiotics, offering potent antibacterial activity and favorable pharmacokinetic properties. While further research is needed to fully elucidate its safety profile and clinical efficacy, solithromycin holds promise for the treatment of respiratory tract infections and other bacterial diseases, addressing an unmet medical need in infectious diseases management.